Abstract: Compounds of Formula I: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.
Type:
Grant
Filed:
August 25, 2017
Date of Patent:
August 31, 2021
Inventors:
Sreenivasarao Vepachedu, Hans J Moebius, Anton Bespalov
Abstract: The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of ?-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.
Abstract: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases.
Type:
Grant
Filed:
May 20, 2016
Date of Patent:
August 24, 2021
Assignee:
AMOREPACIFIC CORPORATION
Inventors:
Byung Gyu Kim, Hyun Woo Jeong, Su Kyung Kim, Si Young Cho, Chan Woong Park, Dae Bang Seo, Wan Gi Kim, Sang Jun Lee
Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.
Abstract: The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same.
Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
Type:
Grant
Filed:
April 30, 2018
Date of Patent:
July 27, 2021
Inventors:
Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Abstract: The present invention relates to a FoxM1 gene splicing modifier selected from a compound of formula (I) or of formula (VI) wherein A and B are as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or delay of progression of cancer.
Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.
Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
Type:
Grant
Filed:
November 21, 2018
Date of Patent:
July 13, 2021
Assignee:
CHIESI FARMACEUTICA S.P.A.
Inventors:
Rajeshwar Motheram, Gopal Krishna, Min Ding, Keith Flood, Kornepati Ramakrishna
Abstract: The present invention relates to a composition for boosting immunity in a person comprising a plurality of minerals, a plurality of vitamins, activated charcoal, coffee beans, vitamin B complex and a carrier, wherein the carrier is an oil-based substance. The composition is an aggregation of the active agents/ingredients conventionally prepared. The present invention allows absorption of multiple active agents/ingredients in the body, consistently. The blend of vitamin and minerals get easily absorbed in the body of a patient without affecting the function of the liver.
Abstract: Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue. The methods are for use in individuals who have been diagnosed with, or are suspected of having or at risk for developing androgen sensitive prostate cancer (AS-CaP), or Castration recurrent CaP (CR-CaP), or benign prostate hyperplasia (BPH). The disclosure includes use of inhibitors of methylthioadenosine phosphorylase (MTAP), and a polyamine analog that upregulates polyamine catabolism by increasing spermidine/spermine N1-acetyl transferase (SAT1) activity, such as methyl-thio-DADMe-Immucillin (MTDIA), and 1),N(11)-bisethylnorspermine (BENSpm), respectively. Pharmaceutical formulations that contain a combination of the inhibitor of the methionine salvage pathway and a polyamine analogue are included, as are kits that contain such agents.
Type:
Grant
Filed:
May 17, 2016
Date of Patent:
June 29, 2021
Assignees:
Health Research, Inc., The Johns Hopkins University
Inventors:
Dominic Smiraglia, Haley Affronti, Robert Casero
Abstract: Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.
Type:
Grant
Filed:
September 4, 2019
Date of Patent:
June 29, 2021
Assignee:
Adamis Pharmaceuticals Corporation
Inventors:
David Clayton Sutherland, James Kyle Zorn, Dennis J. Carlo
Abstract: The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of Formula A1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).
Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
June 29, 2021
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
Abstract: The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
June 15, 2021
Assignee:
Sinntaxis AB
Inventors:
Tadeusz Wieloch, Carin Sjölund, Kerstin Beirup, Karsten Ruscher, Roger Olsson
Abstract: Antimicrobial coating compositions are used to form dried residual antimicrobial coatings on medical dressings including gauze, bandages, gowns and dry wipers. Antimicrobial coating compositions comprise at least one of an organosilane (R1O)3Si—R2—Z, an organic amine R9R10R11N a titanium (IV) species, a 1,2-diol, an ?-hydroxy acid, a ?-hydroxy acid, and an organosilane grafted parylene polymer, wherein R1 is H, alkyl, substituted alkyl, aryl or substituted aryl, R2 is a bivalent linker, Z is a nucleophile, leaving group, or quaternary nitrogen substituent and R9, R10, and R11 are independently H, alkyl, substituted alkyl, aryl, substituted aryl or cyclic.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
June 1, 2021
Assignee:
ALLIED BIOSCIENCE, INC.
Inventors:
Craig Grossman, Gavri Grossman, Daniel Moros, Misagh Alipour, Jie Fang
Abstract: Embodiments herein provide hemostatic compositions comprising a plurality of liquid-expandable articles arranged on a backing material. In general, embodiments include methods for treating hemorrhagic injuries. More specifically, there is provided a method to effect rapid hemostatic response and control hemorrhage by introducing a hemostatic composition into a bleeding wound cavity. An embodiment also provides a method of preparing or manufacturing such a hemostatic composition.